PEAK6 Investments’s Cytokinetics CYTK Stock Holding History

PEAK6 Investments’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.86M	Sell	35,300 -2,900	-8%	-$162K	﹤0.01%	1558
2024 Q2	$2.07M	Sell	38,200 -18,900	-33%	-$1.14M	0.01%	1351
2024 Q1	$4M	Buy	57,100 +12,300	+27%	+$951K	0.01%	959
2023 Q4	$3.74M	Buy	44,800 +29,500	+193%	+$1.07M	0.01%	1050
2023 Q3	$451K	Sell	15,300 -400	-3%	-$13.3K	﹤0.01%	2472
2023 Q2	$512K	Buy	+15,700	New	+$581K	﹤0.01%	2199
2022 Q4	–	Sell	-5,000	Closed	-$242K	–	4582
2022 Q3	$242K	Sell	5,000 -10,700	-68%	-$515K	﹤0.01%	3514
2022 Q2	$512K	Sell	15,700 -56,100	-78%	-$2.26M	﹤0.01%	3798
2022 Q1	$2.64M	Buy	+71,800	New	+$2.55M	0.01%	1623

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PEAK6 Investments's CYTK Position: Q3 2024 in Review

PEAK6 Investments reduced its Cytokinetics (CYTK) stake by 25% in Q3 2024, selling an estimated $184K and leaving 9,730 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

PEAK6 Investments first reported a position in CYTK in Q2 2022 and has held it in 9 quarters since. The position peaked at $706K in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

PEAK6 Investments held 9,730 shares of Cytokinetics worth $514K as of Q3 2024.
PEAK6 Investments sold 3,300 Cytokinetics shares in Q3 2024, an estimated $184K.
Cytokinetics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2296 holding.
PEAK6 Investments first reported a position in Cytokinetics in Q2 2022 and has held it in 9 quarters since.
PEAK6 Investments's Cytokinetics position peaked at $706K in Q2 2024.
347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.